+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating HMBD-501, a HER3-targeted antibody-drug conjugate, in patients with advanced, relapsed, or refractory HER3-expressing solid tumors including melanoma, non-small cell lung cancer, and breast cancer. This Phase 12 trial aims to assess the safety, tolerability, how the drug moves in the body, and early signs of effectiveness. The study is sponsored by Hummingbird Bioscience and includes two parts a dose escalation phase followed by a dose expansion phase. During Phase 1, patients receive increasing doses of HMBD-501 by intravenous injection every three weeks to find the recommended dose for Phase 2. In Phase 2, patients receive this recommended dose to further evaluate the drugs preliminary clinical effects. The dose escalation helps identify the safest and most effective dose schedule for treating these advanced tumors. Participants will have regular visits for treatment, monitoring, and assessments including safety checks and blood tests to measure drug levels. The main outcomes include tracking any side effects during Phase 1 and measuring tumor responses in Phase 2 over about six months. Researchers will also study how the drug behaves in the body and monitor disease control and progression. Participants must follow the visit schedule and study procedures throughout the trial.

Age: 18Years +All GendersPhase 1Phase 2
7 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary cardioprotective and anti-tumor activity of a drug called RC220 combined with doxorubicin in adults with locally advanced unresectable or metastatic solid tumors where doxorubicin could be considered a treatment option. This open-label, phase 1 study is divided into two parts to assess dose escalation and dose expansion in patients with advanced solid tumors. The study has two parts Part 1 involves a fixed-dose doxorubicin monotherapy lead-in cycle to assess tolerability, followed by dose-escalating intravenous infusions of RC220 alone and combined with doxorubicin every 21 days to determine the maximum tolerated combined dose MTCD. Part 2 will evaluate the MTCDs safety, tolerability, and preliminary cardioprotective and anti-tumor effects in an expanded group of patients who have not previously received anthracycline treatment and for whom doxorubicin is indicated. Participants will undergo cycles of treatment starting with doxorubicin alone, then RC220 alone, and then RC220 combined with doxorubicin every 21 days until disease progression, unacceptable toxicity, or withdrawal. Throughout the study, safety and tolerability will be closely monitored, and blood and biomarker samples will be collected. The main outcomes include incidence of dose-limiting toxicities, adverse events, and measures of tumor response and cardiac function over up to 12 months.

Age: 18Years - 80YearsAll GendersPhase 1
9 locations
S

Actively Recruiting

Researchers are evaluating BGB-26808, a HPK1 inhibitor, alone or combined with tislelizumab, an anti-PD-1 antibody, in adults with advanced solid tumors. This phase 1 trial aims to find the recommended dose for BGB-26808 and to assess its safety, tolerability, and preliminary antitumor effects. The study is open-label, nonrandomized in dose escalation, and later includes dose expansion phases.

Age: 18Years +All GendersPhase 1
28 locations
A

Actively Recruiting

Researchers are evaluating KESONOTIDE12, a new drug that inhibits the hGIIA-vimentin protein, in adults with advanced or metastatic solid tumors including prostate, breast, lung, ovarian, glioblastoma, pancreas, and skin cancers. This adaptive phase III trial aims primarily to assess the safety and tolerability of KESONOTIDE12 when given alone. The study also looks at how the drug moves through the body. The trial is open-label and multicenter, enrolling about 20-32 participants in phase I and around 80 in phase II. In phase I, participants receive escalating single doses of KESONOTIDE12 orally at 10mg, 30mg, 60mg, or 120mg to find the best dose with acceptable side effects. Phase II will give participants one of two recommended doses identified earlier, either alone or combined with standard treatments. Treatments are given in 21-day cycles and continue until the cancer worsens, side effects become unacceptable, or other reasons for stopping occur. The adaptive design allows for modifying treatment groups or stopping early based on effectiveness or safety. Participants will be closely monitored with regular assessments including physical exams, vital signs, heart rate, blood pressure, ECGs, laboratory tests, and performance status evaluations. Safety is carefully evaluated in the first 21-day cycle for serious adverse events and dose-limiting toxicities. The study tracks participants until disease progression, withdrawal, or loss to follow-up. The trial runs until October 2027, aiming to provide detailed safety and dosing information for KESONOTIDE12 in solid tumors.

Age: 18Years +All GendersPhase 1Phase 2
3 locations
L

Actively Recruiting

Researchers are investigating maridebart cafraglutide for people with obesity or overweight to evaluate its long-term effects on weight management, safety, and tolerability. This trial is an extension of a previous study trial 20210181 and aims to provide more information about how the drug works over an extended period. It is a phase 3, randomized, double-blind study sponsored by Amgen. Participants will receive different doses of maridebart cafraglutide or placebo depending on their treatment in the previous trial. Some will continue with low dose every 4 weeks, others will be re-randomized to receive medium or high doses on schedules of every 4, 8, or 12 weeks, or placebo injections every 4 weeks. Participants who had placebo before will undergo a dose-escalation phase before starting the high dose treatment. During the study, participants will be monitored for changes in body weight, waist circumference, quality of life, and any side effects or adverse events over about 48 weeks of treatment. The trial will assess how well weight loss is maintained and record any treatment-emergent adverse events up to 60 weeks. Participants will have regular visits for injections and safety assessments throughout the study period.

Age: 18Years - 99YearsAll GendersPhase 3
92 locations
P

Actively Recruiting

Researchers are studying ML-016, a drug being evaluated for safety, tolerability, pharmacokinetics, and anti-tumor effects in adults with advanced or metastatic solid tumors involving the lung andor liver. This open-label, multi-center phase 12 trial includes participants whose cancer is refractory to standard treatments or for whom no curative options exist or are acceptable. The study aims to identify appropriate dosing and assess the drugs impact on tumor control. ML-016 will be given as an intravenous infusion on Day 1 of each 21-day treatment cycle. The study includes a dose-escalation phase to determine safe dosing levels, followed by a dose-expansion phase testing two dose levels in disease-specific groups. Treatment will continue until disease progression or other discontinuation criteria are met. Participants will undergo regular evaluations including blood tests for safety, vital signs, heart function assessments with electrocardiograms and echocardiograms, and imaging studies to measure tumor response. Researchers will monitor adverse events, drug levels, and various survival outcomes over time. The study duration varies based on treatment continuation and follow-up, with primary safety assessments focused on the first 21 days of treatment cycles.

Age: 18Years +All GendersPhase 1Phase 2
3 locations
L

Actively Recruiting

This research aims to assess the long-term safety and effectiveness of the Rigicon Infla 10 Three-Piece Inflatable Penile Prosthesis in men with erectile dysfunction ED. ED is a common male sexual dysfunction linked to various health conditions and affects quality of life. The study follows patients implanted with this device for up to three years to evaluate outcomes. Participants will receive the Rigicon Infla 10 inflatable penile prosthesis as a treatment for ED. After implantation, subjects will be followed according to the study protocol and standard care for ED and related health issues. Follow-up visits are scheduled at 14 days, 6 weeks, 6 months, 12 months, 18 months, 24 months, and 36 months post-procedure. During the study, participants will undergo assessments including safety monitoring for device- or procedure-related adverse events, an objective test of penile rigidity at 12 months, and evaluations of erectile function and self-esteem over time. Researchers will also track durability of the device and collect questionnaire responses. The full participation period may extend up to three years after implantation.

Age: 22Years +MALEPhase Not Applicable
7 locations
S

Actively Recruiting

Researchers are evaluating AU-007, also called imneskibart, in patients with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This first-in-human, open-label Phase 12 study aims to assess the safety, tolerability, and initial effectiveness of AU-007 alone or combined with aldesleukin, with further combinations including avelumab or nivolumab. Participants must have measurable disease and have progressed on or be ineligible for standard treatments. The study includes multiple parts with escalating doses of AU-007 given every two weeks, either alone or with aldesleukin in different dosing schedules. After determining the recommended dose, AU-007 combined with aldesleukin is also tested alongside avelumab or nivolumab in specific patient groups. Treatment is administered in cycles, and different expansion arms focus on particular cancers such as cutaneous melanoma and non-small cell lung cancer. Participants undergo regular assessments including imaging scans to measure disease, blood tests to monitor drug levels and immune response, and safety evaluations throughout treatment and up to 28 days after the last dose. Researchers measure the safety and tolerability of the drugs, establish the maximum tolerated dose, and evaluate early signs of anti-tumor activity. The study monitors participants closely during treatment and follow-up to understand the effects and potential risks of these combinations.

Age: 18Years +All GendersPhase 1Phase 2
17 locations
P

Actively Recruiting

Researchers are evaluating the effects of MAR001 compared to a placebo in adults with elevated triglycerides TG and remnant cholesterol RC. This Phase 2b, randomized, double-blind, placebo-controlled study aims to understand how MAR001 impacts TG levels in people with specific cholesterol conditions. The study includes two parts, focusing on different ranges of baseline triglyceride levels to assess the treatments effects. Participants in Part A with TG levels between 150 and 880 mgdL will receive one of three doses of MAR001 or placebo by subcutaneous injection every four weeks. In Part B, participants with higher TG levels between 450 and 2000 mgdL will receive a dose chosen based on Part A results, also by subcutaneous injection every four weeks. The study consists of a screening period lasting up to 8 weeks, a 24-week treatment phase, and a 12-week safety follow-up with two clinic visits. During the trial, participants will undergo assessments including clinical visits at specified weeks, laboratory tests, and monitoring for safety and treatment effects. Researchers will measure changes in triglyceride levels primarily at 12 weeks, along with secondary outcomes at various time points. The total participation duration includes screening, treatment, and follow-up periods, allowing for comprehensive evaluation of MAR001s impact and safety in this population.

Age: 18Years - 75YearsAll GendersPhase 2
55 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of an investigational drug called mRNA-4359 alone and combined with other immune checkpoint blockerspembrolizumab, ipilimumab, and nivolumabin adults and adolescents with advanced solid tumors. The study includes participants with various cancers such as melanoma, non-small-cell lung cancer NSCLC, bladder cancer, colorectal cancer, and breast cancer who often have not responded to standard treatments. This Phase 12 trial aims to determine safe dosing levels and monitor side effects of these combinations. Participants will receive mRNA-4359 via intramuscular injection either alone or in combination with pembrolizumab, ipilimumab, and nivolumab, which are given by intravenous infusion. Different groups include those receiving mRNA-4359 alone or with pembrolizumab for checkpoint inhibitor refractory melanoma or NSCLC, as well as treatment-naive melanoma or NSCLC patients receiving mRNA-4359 combined with pembrolizumab or with ipilimumab and nivolumab. Dose escalation and expansion phases are included to find recommended dosing and to assess safety and response. During the study, participants will be closely monitored for dose-limiting toxicities, adverse events, and treatment response using imaging and tumor assessments up to 27 or 60 months depending on the group. Tumor biopsies will be collected before and during treatment when possible to study immune responses. Quality of life assessments and long-term survival will also be tracked. The study involves regular visits for treatment administration, monitoring, and evaluations over several months to years.

Age: 12Years +All GendersPhase 1Phase 2
39 locations

1-10 of 12

1